ArticleClinical journal of the American Society of Nephrology : CJASN2010
Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 119 citations in OpenAlex.
- Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis & rheumatology (Hoboken, N.J.) · 2014Trial
- Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis.Current drug targets · 2025Review
- Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review.Biology · 2022Review
- Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis.Rheumatology advances in practice · 2021Article
- Review
- Biologics for childhood systemic vasculitis.Pediatric nephrology (Berlin, Germany) · 2019Review
- Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.Kidney international reports · 2018Article
- Central Nervous System Involvement in ANCA-Associated Vasculitis: What Neurologists Need to Know.Frontiers in neurology · 2018Review
- The European Vasculitis Society 2016 Meeting Report.Kidney international reports · 2017Article
- Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon.Open access rheumatology : research and reviews · 2017Review
- The Search for a Biomarker of Relapse in ANCA-Associated Vasculitis.Journal of the American Society of Nephrology : JASN · 2016Article
- Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.BMC musculoskeletal disorders · 2016Article
- Recent advances in understanding and treating vasculitis.F1000Research · 2016Review
- A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis.Case reports in rheumatology · 2016Article
- Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2015Article
- Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab.Journal of nephrology · 2015Review
- Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.ImmunoTargets and therapy · 2015Review
- Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case series.Clinical rheumatology · 2014Article
- Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.Therapeutic advances in musculoskeletal disease · 2014Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesOngoing randomized trials seek to validate the efficacy of rituximab as an induction agent for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, no studies directly address the role of rituximab as maintenance therapy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This retrospective study reports the authors' experience with continuous rituximab administration in 39 patients in complete or partial remission at the time of rituximab initiation. All 39 patients had at least 1 year of follow-up, and 20 had 2 years of follow-up.
resultsDisease activity, as measured by a modified Birmingham Vasculitis Activity Score, decreased from a median of 1 at baseline to 0 at 12 (P < 0.001) and 24 months (P = 0.02). Three patients experienced nonorgan-threatening flares during 708 patient-months of follow-up. Each flare occurred after at least 20 months of follow-up. The percentage of patients on cytotoxic immunosuppression decreased from 87% at baseline to 41% at 12 months (P < 0.001) and 30% at 24 months (P = 0.002). The percentage of patients on prednisone decreased from 92% at baseline to 59% at 12 months (P < 0.001) and 55% at 24 months (P = 0.02). Two patients developed late-onset neutropenia; both responded to treatment with recombinant granulocyte colony-stimulating factor.
conclusionsThe successful use of continuous anti-B cell therapy in patients with AAV in complete or partial remission is reported. This extends the potential role of rituximab beyond induction to include maintenance therapy. However, more data are required regarding the delayed adverse effects of rituximab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.